List of Qudexy Xr drug patents
Qudexy Xr is owned by Upsher Smith Labs.
Qudexy Xr contains Topiramate.
Qudexy Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Qudexy Xr was authorised for market use on 11 March, 2014.
Qudexy Xr is available in capsule, extended release;oral dosage forms.
Qudexy Xr can be used as treatment of seizures.
The generics of Qudexy Xr are possible to be released after 19 March, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(10 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic